Many types of tumours that were considered untreatable only a few years ago currently show promising clinical response rates upon treatment with biologicals, such as monoclonal antibodies targeting so-called immune check-point inhibitors (ICIs), like PD-1/PD-L1 and CTLA-4 [1,2]. This evidence concerns the gene CTLA4 and neoplasm.